Fiducian Technology Fund



Monthly Report - April 2025

Fund description

The Fiducian Technology Fund allows investors to participate directly in a blend of some of the leading technology funds available worldwide. Utilising the Fiducian "Manage the Manager" process, fund managers have been chosen to balance exposure in terms of region and sector.

Managers are able to invest in technology companies anywhere in the world that can benefit from leading-edge technology and can demonstrate significant earnings growth prospects.

Investors must bear in mind that investing in a fund of this nature can involve periods of very high volatility, although superior long-run returns can likely be achieved if investors are prepared to hold investments for periods of at least 9 years.

Fund facts

Portfolio manager: Conrad Burge ARSN: 093 544 337 APIR code: FPS0010AU Benchmark: NASDAQ-100 Index (AUD) Current fund size: \$231 million (April 2025) Management cost: 1.36% Total management costs: 1.42% Application/Exit fee: Nil Inception Date: June 2000

Wellington Tech Wellington Biotech Invesco Nasdaq 100 ETF Loftus Peak

Manager

 Style
 Sector


 Value
 Core
 Growth
 IT
 Biotech
 Blend

 •
 •
 •
 •
 •
 •


Performance and Risk

After fee returns as at	30 April 2025							
	1 Mth	3 Mth	6 Mth	1 Yr	3 Yrs	5 Yrs	7yrs	10 Yrs
Fund	0.4%	-12.9%	-2.4%	8.6%	7.2%	6.8%	10.3%	12.0%
Index	-1.0%	-10.9%	1.2%	14.7%	17.2%	11.4%	14.0%	13.0%
Excess	1.3%	-2.0%	-3.6%	-6.1%	-10.0%	-4.7%	-3.7%	-1.0%

Risk Exposure				
	1 Yr	3 Yrs	5 Yrs	10 Yrs
Fund Volatility (Std Dev %)	14.8%	16.5%	16.4%	16.0%
Benchmark (Std Dev %)	14.1%	13.3%	13.9%	13.6%
Beta	0.93	1.05	1.01	1.02
Tracking Error (% pa)	3.7%	8.3%	8.2%	7.7%



Geographic exposures and current manager weights



Fiducian Technology Fund



Monthly Report - April 2025

Market Commentary and Outlook

The global economy is expected to slow marginally this year, according to the latest forecast provided by the International Monetary Fund (IMF). Global growth is forecast to be at 2.8% this year and 3.0% in 2026, which is below the IMF's previous forecast of 3.3% each year (around the long-term trend rate). In the IMF's words, this lowering of its growth forecasts is due to 'the swift escalation of trade tensions and extremely high levels of policy uncertainty', after 'a series of new tariff measures by the US and countermeasures by its trading partners'. The IMF adds that 'if countries de-escalate from their current tariff stance, the outlook could immediately brighten'. In other words, if positive trade deals are able to be completed over the near-term, investors could potentially quickly regain confidence and enable an economic rebound, at least for some economies.

Uncertainty surrounding US trade policies and growing fears of a recession have caused volatility across equity markets, with the broad US stock market (S&P 500 Accumulation Index) falling 0.7% over the month. The Australian market (ASX 200 Accumulation Index) rose 3.6% over the same period, leading up to the federal election. The Australian dollar gained relative to the US dollar. Most commodity prices declined, except for gold.

Until recently, key global share markets had been 'pricing-in' a shift by central banks towards less restrictive monetary policy, which led to strong returns for equity investors. However, equity markets experienced extreme volatility in April, falling heavily after the announcement early in the month that the US would be implementing hefty tariffs on most imports and then rebounding after the announcement of a 90-day pause.

Fund Commentary

The Fiducian Technology Fund gained 0.4% in April, which was above the index return of -1.0%. For the 12 months to the end of April, the Fund returned 8.6%.

Technology stocks were higher in April, with the NASDAQ 100 index gaining 1.6%, outperforming the broader US stock market which declined by 0.7%.

Heavy price falls in major technology stocks in early April saw valuations move towards historically attractive levels, assuming that strong earnings growth can be sustained. Assuming too that an improved balance in international trade relations can be achieved over coming months, the sector could experience further recovery over the nearterm.

The longer-term outlook for the technology sector remains positive, as the need to invest in innovation to drive productivity gains across areas such as artificial intelligence, manufacturing, life sciences and sustainable energy should prove to be a structural tailwind for technology companies. Moreover, the sector may continue to benefit from favourable sentiment surrounding the outlook for AI, despite recent short-term corrections.

The Fund remains well diversified between geographies and sectors, and companies held are a blend of established sector leaders plus emerging technology businesses. An overweight positon in the Information Technology sector relative to Biotechnology reflects the better growth opportunities currently available in that part of the market. The largest geographical exposure is to North America which makes up 89.4% of the fund, followed by Asia at 5.2%.

Top stock holdi	ngs and sector weigh	ts	
Stock	Industry	Weight	Biotechnology Cash, 2.5%
Nvidia Corp	Semiconductors	9.2%	
Microsoft Corp	Software	8.0%	9.0%
Taiwan Semiconductor	Semiconductors	5.6%	
Amazon.Com	Internet	5.4%	
Broadcom	Semiconductors	5.2%	
Netflix Inc	Internet	3.7%	
Apple Inc	Computers	3.5%	Information
Meta Platforms	Internet	3.3%	Technology,
Mastercard	Diversified Financials	2.9%	88.6%
Uber Technologies	Software	2.7%	

Fiducian Investment Management Services Limited

Issued by Fiducian Investment Management Services Limited ABN 28 602 441 814 AFS Licence number 468211. This document provides general information only. It does not have regard to your objectives, financial situation or needs. We recommend that you seek financial planning advice, and consider whether this investment is appropriate to your objectives, financial situation and needs before making any investment decision.

The information has been compiled from sources considered reliable, but is not guaranteed. Past performance is not indicative of future performance and we do not guarantee the performance of the Fund or any specific rate of return. Potential investors should also obtain and consider the relevant Target Market Determination (TMD) and Product Disclosure Statement (PDS) (available from your financial adviser and via fiducian.com.au) before making a decision about whether to acquire or continue to hold any financial product.